{"id":1631,"date":"2023-06-25T17:28:42","date_gmt":"2023-06-25T17:28:42","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/amisulpride\/"},"modified":"2023-06-25T19:58:28","modified_gmt":"2023-06-25T19:58:28","slug":"amisulpride","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/amisulpride\/","title":{"rendered":"Amisulpride"},"content":{"rendered":"

<\/p>\n

Amisulpride<\/h1>\n

CLINICAL USE<\/h3>\n

Treatment of acute and chronic
\nschizophrenia<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

50\u20131200 mg daily (in divided doses if
\n>300 mg); varies according to indication<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           :
    \n369.5<\/li>\n
  • %Protein binding                           :
    \n16<\/li>\n
  • %Excreted unchanged in urine     :
    \n50<\/li>\n
  • Volume of distribution (L\/kg)       :
    \n5.8<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :
    \n12\/Unchanged<\/p>\n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n

    30\u201360 Reduce dose by 50%
    \n10\u201330 Use a third of the dose.<\/li>\n

  • <10           :
    \nUse with caution. Start with
    \nminimum dose and increase
    \naccording to patient\u2019s response<\/p>\n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :
    \nNot dialysed. Dose as in
    \nGFR <10 mL\/min<\/li>\n
  • HD                     :
    \nPoorly dialysed. Dose as in
    \nGFR <10 mL\/min<\/li>\n
  • HDF\/high flux   :
    \nUnknown dialysability. Dose as in
    \nGFR <10 mL\/min<\/li>\n
  • CAV\/VVHD      :
    \nPoorly dialysed. Dose as in
    \nGFR=10\u201330 mL\/min<\/p>\n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Alcohol: may enhance CNS effects ofalcohol<\/li>\n
  • Anaesthetics: enhanced hypotensive effect<\/li>\n
  • Analgesics: increased risk of convulsionswith tramadol; enhanced hypotensive and
    \nsedative effects with opioids<\/li>\n
  • Antiarrhythmics: increased risk ofventricular arrhythmias with antiarrhythmics that prolong the QT interval;
    \navoid concomitant use with amiodarone,
    \ndisopyramide and procainamide (risk of
    \nventricular arrhythmias)<\/li>\n
  • Antibacterials: avoid concomitant use withparenteral erythromycin (increased risk of
    \nventricular arrhythmias)<\/li>\n
  • Antidepressants: increased level oftricyclics<\/li>\n
  • Antiepileptics: antagonises anticonvulsanteffect<\/li>\n
  • Antihypertensives: increased risk ofhypotension<\/li>\n
  • Antimalarials: avoid concomitant use withartemether\/lumefantrine
    \nAntipsychotics: increased risk of<\/p>\n

    ventricular arrhythmias with sertindole \u2013
    \navoid concomitant use<\/li>\n

  • Antivirals: concentration possiblyincreased by ritonavir
    \nAnxiolytics & hypnotics: increased<\/p>\n

    sedative effects<\/li>\n

  • Atomoxetine: increased risk of ventriculararrhythmias<\/li>\n
  • Beta-blockers: increased risk of ventriculararrhythmias with sotalol
    \nDiuretics: increased risk of ventricular<\/p>\n

    arrhythmias due to hypokalaemia<\/li>\n

  • Pentamidine: increased risk of ventriculararrhythmias \u2013 avoid<\/li>\n
  • Sibutramine: increased risk of CNStoxicity \u2013 avoid concomitant use
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n

    Elimination half-life is unchanged in<\/p>\n

    patients with renal insufficiency, while
    \nsystemic clearance is reduced by a factor
    \nof 2.5\u20133. The area under the curve of
    \namisulpride in mild renal failure is
    \nincreased 2-fold, and almost 10-fold in
    \nmoderate renal failure. Experience is
    \nlimited and there is no data with doses
    \n>50 mg<\/li>\n","protected":false},"excerpt":{"rendered":"

    Amisulpride CLINICAL USE Treatment of acute and chronic schizophrenia DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1631","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1631"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1631\/revisions"}],"predecessor-version":[{"id":2926,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1631\/revisions\/2926"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}